Equity ETFs M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound By Max ChenSeptember 12, 2016
Equity ETFs For Biotech ETFs, It’s All About U.S. Presidential Politics By Tom LydonSeptember 1, 2016
Equity ETFs Clinton Mylan Attack Reminds Biotech ETF Investors of Election Risks By Max ChenAugust 25, 2016
Equity ETFs Pfizer Acquires Anacor, Reviving M&A Bets in Biotech Sector, ETFs By Max ChenMay 16, 2016
Equity ETFs Health Care ETFs Can Still Strengthen on Increased M&A Activity By Max ChenApril 28, 2016